North Bristol NHS Trust is a centre of excellence for the delivery of care for people with renal impairment. We are also home to the main kidney transplant centre in the South West.
Our experienced research team works collaboratively with a number of other research teams including diabetes and cancer to deliver cross-functional complex studies in addition to studies focused solely within the renal service.
Please speak to the person treating you to find out if there is a research study that may be able to help you.
Studies in follow-up:
EMPA-KIDNEY is a clinical trial aiming to test whether taking a medication called empagliflozin lowers the risk of worsening kidney disease or heart disease in patients with kidney disease.
Empagliflozin was originally developed to treat people with diabetes. In a large clinical trial, empagliflozin reduced the number of deaths from heart disease in people who already had both heart disease and diabetes. The same clinical trial suggested that this medication could reduce the development or worsening of kidney disease. There is good reason to believe the medication could benefit people with kidney disease whether they have diabetes or not.
EMPA-KIDNEY aims to recruit about 5000 participants with chronic kidney disease internationally (of which about 1000 will be in the UK). Half of the participants will take empagliflozin 10mg once daily and half will receive a matching inactive pill (placebo). The trial is designed to be simple to run: extra effort and work for volunteer participants and collaborating hospital teams will be kept to a minimum, and only essential information will be collected.
Participants will be followed in clinics 3 times over the first 6 months and then 6 monthly. At each visit they will have a measure of kidney function and blood pressure made and information about their health recorded. Some visits will also include provision of a urine sample. These study clinics will be run by research staff trained on study procedures. The study will continue until the study-required number of clinical outcomes have occurred which is estimated to take about 3-4 years.
Principal Investigator: Dr James Bushnell
Study Completion: 13/06/2022
Local Ref: 4212
PREDICT: Thinking about Pregnancy Risk in Women with Kidney Disease
Currently, there is no robust evidence about how women with Chronic Kidney Disease (CKD) perceive pregnancy risk. The aim of this research is to improve understanding of women with CKD’s perception of risk in pregnancy.
In order to provide appropriate pre-pregnancy and antenatal counselling including accurate presentation of risk of pregnancy outcomes, it is important to establish how do women with CKD perceive their pregnancy risk. In addition, to facilitate discussion about pregnancy for women with CKD, it is critical to understand key biopsychosocial factors influencing their risk perceptions.
This study will be conducted in two phases. In phase one, risk perceptions in women with CKD who are contemplating pregnancy will be quantitatively measured and potential influencing biopsychosocial factors assessed including their illness perceptions, quality of life, anxiety, depression and perceived social support. Demographic, medical and pregnancy histories will also be collected. Phase one findings will establish how do women with CKD perceive their risk and the biopsychosocial factors associated with risk perception will be established.
In phase two, perception of risk and intentions will be qualitatively explored in women with CKD who perceive high and low degrees of risk. This sub-study will facilitate understanding about which factors and experiences impact risk perception and their relationship with pregnancy intentions.
This study will establish whether there is a greater need for risk communication for women with CKD to develop accurate risk perceptions and will insight into key factors which drive risk perceptions which will facilitate effective future risk communication. The findings of this research will inform how a clinical predictive tool is delivered to CKD women (PREDICT – Pregnancy-associated progression of chronic kidney Disease: development of a Clinical predictive Tool).
Principal Investigator: TBC
Study Completion: TBC
Local Ref: 4910
Become one of the thousands of people taking part in research every day within the NHS.
Find out more about our research and how we're working to improve patient care.